HRP20100159T1 - Upotreba hidrofilnog matriksa koji se sastoji od derivata poliakrilne kiseline, celuloznog etera i sredstva za raspadanje u proizvodnji medikamenta za liječenje ženskih genitalnih poremećaja - Google Patents
Upotreba hidrofilnog matriksa koji se sastoji od derivata poliakrilne kiseline, celuloznog etera i sredstva za raspadanje u proizvodnji medikamenta za liječenje ženskih genitalnih poremećaja Download PDFInfo
- Publication number
- HRP20100159T1 HRP20100159T1 HR20100159T HRP20100159T HRP20100159T1 HR P20100159 T1 HRP20100159 T1 HR P20100159T1 HR 20100159 T HR20100159 T HR 20100159T HR P20100159 T HRP20100159 T HR P20100159T HR P20100159 T1 HRP20100159 T1 HR P20100159T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- polyacrylic acid
- starches
- matrix
- disintegrant
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title claims abstract 11
- 229920002125 Sokalan® Polymers 0.000 title claims abstract 10
- 239000004584 polyacrylic acid Substances 0.000 title claims abstract 9
- 229920003086 cellulose ether Polymers 0.000 title claims abstract 6
- 239000007884 disintegrant Substances 0.000 title claims abstract 6
- 208000017443 reproductive system disease Diseases 0.000 title claims abstract 4
- 238000004519 manufacturing process Methods 0.000 title claims abstract 3
- 239000003814 drug Substances 0.000 title 1
- 229920002472 Starch Polymers 0.000 claims abstract 8
- 238000009472 formulation Methods 0.000 claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 8
- 235000019698 starch Nutrition 0.000 claims abstract 8
- 210000004392 genitalia Anatomy 0.000 claims abstract 5
- 229920000881 Modified starch Polymers 0.000 claims abstract 4
- 235000019426 modified starch Nutrition 0.000 claims abstract 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims abstract 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims abstract 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims abstract 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract 2
- 229920000856 Amylose Polymers 0.000 claims abstract 2
- 241000894006 Bacteria Species 0.000 claims abstract 2
- 229920002261 Corn starch Polymers 0.000 claims abstract 2
- 241000233866 Fungi Species 0.000 claims abstract 2
- 241000700605 Viruses Species 0.000 claims abstract 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims abstract 2
- 235000010443 alginic acid Nutrition 0.000 claims abstract 2
- 239000000783 alginic acid Substances 0.000 claims abstract 2
- 229920000615 alginic acid Polymers 0.000 claims abstract 2
- 229960001126 alginic acid Drugs 0.000 claims abstract 2
- 150000004781 alginic acids Chemical class 0.000 claims abstract 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract 2
- 229920002678 cellulose Polymers 0.000 claims abstract 2
- 235000010980 cellulose Nutrition 0.000 claims abstract 2
- 239000008120 corn starch Substances 0.000 claims abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract 2
- 229920001592 potato starch Polymers 0.000 claims abstract 2
- 235000010413 sodium alginate Nutrition 0.000 claims abstract 2
- 239000000661 sodium alginate Substances 0.000 claims abstract 2
- 229940005550 sodium alginate Drugs 0.000 claims abstract 2
- 239000007787 solid Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 229920013820 alkyl cellulose Polymers 0.000 claims 2
- 229940121375 antifungal agent Drugs 0.000 claims 2
- 239000003429 antifungal agent Substances 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 150000005846 sugar alcohols Chemical class 0.000 claims 2
- -1 triazole derivatives Chemical class 0.000 claims 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims 1
- RWBRUCCWZPSBFC-RXRZZTMXSA-N (20S)-20-hydroxypregn-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](O)C)[C@@]1(C)CC2 RWBRUCCWZPSBFC-RXRZZTMXSA-N 0.000 claims 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical class NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 206010048461 Genital infection Diseases 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims 1
- 229920000148 Polycarbophil calcium Polymers 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Chemical class 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 230000001857 anti-mycotic effect Effects 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000002543 antimycotic Substances 0.000 claims 1
- 229940064004 antiseptic throat preparations Drugs 0.000 claims 1
- 229940121357 antivirals Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 1
- 239000000227 bioadhesive Substances 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 229960003749 ciclopirox Drugs 0.000 claims 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical group ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims 1
- 229960004375 ciclopirox olamine Drugs 0.000 claims 1
- 229960002227 clindamycin Drugs 0.000 claims 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- 229930182833 estradiol Natural products 0.000 claims 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims 1
- 229960001348 estriol Drugs 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 229960002568 ethinylestradiol Drugs 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 1
- 229960004413 flucytosine Drugs 0.000 claims 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical class COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims 1
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 229960002899 hydroxyprogesterone Drugs 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229960004716 idoxuridine Drugs 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 229940041028 lincosamides Drugs 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 229940041033 macrolides Drugs 0.000 claims 1
- 229960004616 medroxyprogesterone Drugs 0.000 claims 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 claims 1
- UXYRZJKIQKRJCF-TZPFWLJSSA-N mesterolone Chemical compound C1C[C@@H]2[C@@]3(C)[C@@H](C)CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C UXYRZJKIQKRJCF-TZPFWLJSSA-N 0.000 claims 1
- 229960005272 mesterolone Drugs 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 150000002780 morpholines Chemical class 0.000 claims 1
- 229960002136 nifuratel Drugs 0.000 claims 1
- SRQKTCXJCCHINN-NYYWCZLTSA-N nifuratel Chemical compound O=C1OC(CSC)CN1\N=C\C1=CC=C([N+]([O-])=O)O1 SRQKTCXJCCHINN-NYYWCZLTSA-N 0.000 claims 1
- KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 claims 1
- 229960004911 nomegestrol Drugs 0.000 claims 1
- 229940053934 norethindrone Drugs 0.000 claims 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims 1
- 229960001179 penciclovir Drugs 0.000 claims 1
- 150000002960 penicillins Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003075 phytoestrogen Substances 0.000 claims 1
- 229960001237 podophyllotoxin Drugs 0.000 claims 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims 1
- 229950005134 polycarbophil Drugs 0.000 claims 1
- 150000004291 polyenes Chemical class 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 229960002847 prasterone Drugs 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical class NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 claims 1
- GGOZGYRTNQBSSA-UHFFFAOYSA-N pyridine-2,3-diol Chemical class OC1=CC=CN=C1O GGOZGYRTNQBSSA-UHFFFAOYSA-N 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 229940040944 tetracyclines Drugs 0.000 claims 1
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 claims 1
- 229960001023 tibolone Drugs 0.000 claims 1
- 229960005053 tinidazole Drugs 0.000 claims 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 claims 1
- 229960004880 tolnaftate Drugs 0.000 claims 1
- 239000002132 β-lactam antibiotic Substances 0.000 claims 1
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Upotreba hidrofilnog matriksa koji se sastoji od: a) najmanje jednog derivata poliakrilne kiseline, u količini od 0,5-40 % s obzirom na težinu matriksa; b) najmanje jednog celuloznog etera; ic) najmanje jednog sredstva za raspadanje; te od najmanje jednog farmaceutski prihvatljivog aktivnog principa, naznačena time što je navedeni hidrofilni matriks namijenjen proizvodnji formulacije za liječenje ženskih genitalnih poremećaja, gdje najmanje jedno sredstvo za raspadanje se bira između modificiranih celuloza, poput umrežene natrij-karboksimetilceluloze, umreženog polivinilpirolidona, poput krospovidona, prirodnih škrobova, poput kukuruznog škroba, krumpirovog škroba, izravno kompresibilnih škrobova, modificiranih škrobova, poput karboksimetilškrobova i natrij-karboksimetilškroba, škrobnih derivata, poput amiloze, alginske kiseline i natrijevog alginata, mikrokristalne celuloze, te gdje navedeni ženski genitalni poremećaji su hipotrofija spolnih organa, atrofija spolnih organa, gubitak elastičnosti spolnih organa, suhoća rodnice, infekcije vrata maternice i/ili rodnice uzrokovane gljivicama, bakterijama, protozoama ili virusima. Patent sadrži još 21 patentni zahtjev.
Claims (22)
1. Upotreba hidrofilnog matriksa koji se sastoji od:
a) najmanje jednog derivata poliakrilne kiseline, u količini od 0,5-40 % s obzirom na težinu matriksa;
b) najmanje jednog celuloznog etera; i
c) najmanje jednog sredstva za raspadanje; te od najmanje jednog farmaceutski prihvatljivog aktivnog principa,
naznačena time što je navedeni hidrofilni matriks namijenjen proizvodnji formulacije za liječenje ženskih genitalnih poremećaja, gdje najmanje jedno sredstvo za raspadanje se bira između modificiranih celuloza, poput umrežene natrij-karboksimetilceluloze, umreženog polivinilpirolidona, poput krospovidona, prirodnih škrobova, poput kukuruznog škroba, krumpirovog škroba, izravno kompresibilnih škrobova, modificiranih škrobova, poput karboksimetilškrobova i natrij-karboksimetilškroba, škrobnih derivata, poput amiloze, alginske kiseline i natrijevog alginata, mikrokristalne celuloze, te gdje navedeni ženski genitalni poremećaji su hipotrofija spolnih organa, atrofija spolnih organa, gubitak elastičnosti spolnih organa, suhoća rodnice, infekcije vrata maternice i/ili rodnice uzrokovane gljivicama, bakterijama, protozoama ili virusima.
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što navedeno najmanje jedno sredstvo za raspadanje je umrežena natrij-karboksimetilceluloza.
3. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što navedeni najmanje jedan derivat poliakrilne kiseline dolazi u količinama od 2-40 %, po mogućnosti 2-30 %, navedeni najmanje jedan celulozni eter dolazi u količinama od 30-90 %, a navedeno najmanje jedno sredstvo za raspadanje dolazi u količinama od 2-50 %, s obzirom na težinu matriksa.
4. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što navedeni najmanje jedan derivat poliakrilne kiseline dolazi u količinama od 1-20 %, navedeni najmanje jedan celulozni eter dolazi u količinama od 40-80 %, a navedeno najmanje jedno sredstvo za raspadanje dolazi u količinama od 5-40 %, s obzirom na težinu matriksa.
5. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što navedeni najmanje jedan derivat poliakrilne kiseline je poliakrilna kiselina umrežena s polialkenil-eterima šećera ili polialkohola, po mogućnost s karbomerom.
6. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što navedeni najmanje jedan derivat poliakrilne kiseline je poliakrilna kiselina umrežena s divinil-glikolom, po mogućnosti s polikarbofilom.
7. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što navedeni najmanje jedan celulozni eter se bira između hidroksilakilceluloze, alkilceluloze, karboksimetilceluloze ili njezine soli.
8. Upotreba u skladu s patentnim zahtjevom 7, naznačena time što navedenu hidroksilakilcelulozu se bira između hidroksipropilmehilceluloze, hidroksilpropilceluloze i hidroksiehilceluloze; i/ili navedenu alkilcelulozu se bira između metilceluloze i etilceluloze.
9. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što navedena formulacija je čvrsta.
10. Čvrsta formulacija u skladu s patentnim zahtjevom 9, naznačena time što navedeni matriks je prisutan u količini od otprilike 5-60 %, po mogućnosti 20-40 %, a navedeni najmanje jedan aktivni princip u količinama od otprilike 2-70 %, po mogućnosti 5-50 %, s obzirom na težinu matriksa.
11. Upotreba u skladu s patentnim zahtjevom 9, naznačena time što uključuje farmaceutski prihvatljiva punila, pomoćne tvari i/ili adjuvanse.
12. Upotreba u skladu s patentnim zahtjevom 9, naznačena time što navedeni najmanje jedan aktivni princip se bira između antimikotika, antibiotika, antivirusnih, antimikrobnih sredstava ili kemoterapeutika i hormona.
13. Upotreba u skladu s patentnim zahtjevom 12, naznačena time što navedeni antimikotik se bira između hidroksi-2-piridonskih spojeva, imidazolskih derivata, polienskih derivata, alilaminskih derivata, triazolskih derivata, morfolinskih derivata, grizeofulvinskih spojeva, kiselih spojeva, tolnaftata, flucitozina i njihovih soli.
14. Upotreba u skladu s patentnim zahtjevom 12, naznačena time što navedeni antimikotik je ciklopiroks ili ciklopiroks olamin.
15. Upotreba u skladu s patentnim zahtjevom 12, naznačena time što navedeni antibiotik ili antimikrobno sredstvo se bira između aminoglikozida, tetraciklina, makrolida, kinolona, sulfonamida samih ili u kombinaciji s diaminopiridinima, penicilinskih spojeva, cefalosporina i drugih β-laktamskih antibiotika, linkozamida, antiprotozoika, antibakterijskih sredstava, antiseptika i njihovih soli.
16. Upotreba u skladu s patentnim zahtjevom 12, naznačena time što navedeni antibiotik se bira između nifuratela, metronidazola, tinidazola, klindamicina.
17. Upotreba u skladu s patentnim zahtjevom 12, naznačena time što navedeno antivirusno sredstvo se bira između idoksuridina, aciklovira, penciklovira, podofilotoksina ili imikvimoda.
18. Upotreba u skladu s patentnim zahtjevom 12, naznačena time što navedeni hormon se bira između estradiola, ethinilestradiola, estriola, promestriena, hidroksiprogesterona, progesterona, medroksiprogesterona, dihidrogesterona, nomegestrola, noretisterona, tibolona, testosterona, prasterona, mesterolona ili bilo kojeg fitoestrogena.
19. Upotreba u skladu s patentnim zahtjevom 11, naznačena time što navedenu pomoćnu tvar se bira između askorbinske kiseline, mliječne kiseline i njihovih soli.
20. Upotreba u skladu s patentnim zahtjevom 9, naznačena time što navedena čvrsta formulacija je tableta, po mogućnosti bioadhezivna tableta.
21. Upotreba u skladu s patentnim zahtjevom 9, naznačena time što navedena čvrsta formulacija je formulacija s kontroliranim otpuštanjem.
22. Upotreba u skladu s patentnim zahtjevom 9, naznačena time što navedenu čvrstu formulaciju se primjenjuje u šupljinu rodnice.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06116269A EP1872775A1 (en) | 2006-06-29 | 2006-06-29 | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
| PCT/EP2007/056185 WO2008000683A1 (en) | 2006-06-29 | 2007-06-21 | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100159T1 true HRP20100159T1 (hr) | 2010-05-31 |
Family
ID=37433668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100159T HRP20100159T1 (hr) | 2006-06-29 | 2010-03-18 | Upotreba hidrofilnog matriksa koji se sastoji od derivata poliakrilne kiseline, celuloznog etera i sredstva za raspadanje u proizvodnji medikamenta za liječenje ženskih genitalnih poremećaja |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8865201B2 (hr) |
| EP (2) | EP1872775A1 (hr) |
| JP (1) | JP5205374B2 (hr) |
| KR (1) | KR101443149B1 (hr) |
| CN (2) | CN101478951A (hr) |
| AR (1) | AR061771A1 (hr) |
| AT (1) | ATE455534T1 (hr) |
| BR (1) | BRPI0713298A2 (hr) |
| CA (1) | CA2652226C (hr) |
| CO (1) | CO6140022A2 (hr) |
| CY (1) | CY1109910T1 (hr) |
| DE (1) | DE602007004486D1 (hr) |
| DK (1) | DK2032123T3 (hr) |
| EA (1) | EA018257B1 (hr) |
| ES (1) | ES2339069T3 (hr) |
| HK (1) | HK1128587A1 (hr) |
| HR (1) | HRP20100159T1 (hr) |
| MA (1) | MA30597B1 (hr) |
| MX (1) | MX2008016508A (hr) |
| NO (1) | NO20090095L (hr) |
| PL (1) | PL2032123T3 (hr) |
| PT (1) | PT2032123E (hr) |
| RS (1) | RS51279B (hr) |
| SI (1) | SI2032123T1 (hr) |
| WO (1) | WO2008000683A1 (hr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2344673B1 (es) | 2008-08-07 | 2011-05-03 | Italfarmaco, S.A. | Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral. |
| EP2163240A1 (en) * | 2008-09-12 | 2010-03-17 | Universita' Degli Studi Di Genova | A method for the production of bioadhesive compact matrices |
| EP2344121B1 (en) * | 2008-10-23 | 2017-07-12 | Henkel IP & Holding GmbH | Vaginal pellets comprising debranched starch |
| ES2344675B1 (es) * | 2008-12-19 | 2011-04-28 | Italfarmaco, S.A. | Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular. |
| EP2243482A1 (en) * | 2009-04-20 | 2010-10-27 | Polichem SA | Use of nifuratel to treat infections caused by atopobium species |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| HUE055562T2 (hu) | 2011-11-23 | 2021-11-29 | Therapeuticsmd Inc | Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| BR112016009008B8 (pt) * | 2013-10-22 | 2023-01-31 | Therapeuticsmd Inc | Uso de estradiol e/ou hemi-hidrato de estradiol e de um agente solubilizante compreendendo um óleo de cadeia média para a preparação de um pessário para o tratamento de atrofia vulvovaginal e pessário que compreende estradiol |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| CN105796520A (zh) * | 2014-12-29 | 2016-07-27 | 四川滇虹医药开发有限公司 | 一种缓释型硝酸布康唑直压片剂及其制备方法 |
| WO2016115639A1 (en) | 2015-01-23 | 2016-07-28 | Biocidium Biopharmaceuticals Inc. | Anti-bacterial compositions |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| US11026883B2 (en) * | 2016-10-13 | 2021-06-08 | Catalent U.K. Swindon Zydis Limited | Lyophilized pharmaceutical compositions for vaginal delivery |
| GB201808567D0 (en) * | 2018-05-24 | 2018-07-11 | Douglas Pharmaceuticals Ltd | Pharmaceutical compositions |
| CN109010320B (zh) * | 2018-09-18 | 2021-09-14 | 浙江汇能生物股份有限公司 | 一种双释型聚卡波非钙颗粒剂及制备方法和畜禽中的应用 |
| CN114129530A (zh) * | 2021-12-08 | 2022-03-04 | 南京康川济医药科技有限公司 | 一种黄体酮缓释组合物及其制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2096744A (en) | 1932-10-27 | 1937-10-26 | Schering Corp | Hydrogenation products of follicle hormones and method of producing same |
| US2232438A (en) | 1934-08-04 | 1941-02-18 | Schering Corp | Unsaturated pregnanolones and pregnandiones and a method of producing the same |
| US2243887A (en) | 1935-11-09 | 1941-06-03 | Schering Corp | Tertiary carbinols of the cyclopentano-polyhydrophenanthrene series and a method of producing the same |
| US2251939A (en) | 1935-11-22 | 1941-08-12 | Schering Corp | Tertiary alcohols of the cyclopentano polyhydro phenanthrene series and a method of producing the same |
| US2379832A (en) | 1936-06-02 | 1945-07-03 | Schering Corp | Process for the manufacture of unsaturated ketones of the cyclopentano polyhydro phenanthrene series |
| CH202847A (de) | 1937-06-26 | 1939-02-15 | Chem Ind Basel | Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe. |
| US2265976A (en) | 1937-10-25 | 1941-12-09 | Schering Corp | Tertiary alcohols of the estrane series and their derivatives and a process for their manufacture |
| US2314185A (en) | 1939-09-01 | 1943-03-16 | Zondek Bernhard | Process for the manufacture of progesterone |
| BE665514A (hr) | 1964-06-16 | |||
| NL146838B (nl) | 1966-06-24 | 1975-08-15 | Organon Nv | Werkwijze voor het bereiden van (delta)5(10)-3- keto-19-norsteroiden. |
| JPS5562012A (en) * | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
| US7744916B2 (en) * | 1997-06-11 | 2010-06-29 | Umd, Inc. | Coated vaginal device for delivery of anti-migraine and anti-nausea drugs |
| US6416779B1 (en) * | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
| US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
| UA74168C2 (uk) | 1999-10-05 | 2005-11-15 | Коламбіа Леборетеріс (Бермуда) Лімітед | Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу |
| HUP0301465A3 (en) | 2000-06-23 | 2006-07-28 | Teva Pharma | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| FR2813865B1 (fr) | 2000-09-08 | 2002-12-20 | Rexam Sofab | Dispositif a buse unique pour la distribution selective de deux produits |
| CA2422424C (en) | 2000-09-19 | 2009-12-01 | Cima Labs, Inc. | Pharmaceutical compositions for rectal and vaginal administration |
| NZ528377A (en) * | 2001-03-27 | 2005-05-27 | Galen Chemicals Ltd | Intravaginal drug delivery devices for the administration of an antimicrobial agent |
| US6899890B2 (en) * | 2002-03-20 | 2005-05-31 | Kv Pharmaceutical Company | Bioadhesive drug delivery system |
| CN1302764C (zh) | 2005-01-10 | 2007-03-07 | 凌沛学 | 一种妇科用药阴道凝胶片 |
-
2006
- 2006-06-29 EP EP06116269A patent/EP1872775A1/en not_active Withdrawn
-
2007
- 2007-06-21 US US12/308,786 patent/US8865201B2/en not_active Expired - Fee Related
- 2007-06-21 WO PCT/EP2007/056185 patent/WO2008000683A1/en active Application Filing
- 2007-06-21 DE DE602007004486T patent/DE602007004486D1/de active Active
- 2007-06-21 MX MX2008016508A patent/MX2008016508A/es active IP Right Grant
- 2007-06-21 EA EA200900087A patent/EA018257B1/ru not_active IP Right Cessation
- 2007-06-21 CA CA2652226A patent/CA2652226C/en not_active Expired - Fee Related
- 2007-06-21 RS RSP-2010/0045A patent/RS51279B/sr unknown
- 2007-06-21 PL PL07730288T patent/PL2032123T3/pl unknown
- 2007-06-21 EP EP07730288A patent/EP2032123B1/en active Active
- 2007-06-21 ES ES07730288T patent/ES2339069T3/es active Active
- 2007-06-21 SI SI200730193T patent/SI2032123T1/sl unknown
- 2007-06-21 PT PT07730288T patent/PT2032123E/pt unknown
- 2007-06-21 KR KR1020087032076A patent/KR101443149B1/ko not_active IP Right Cessation
- 2007-06-21 CN CNA2007800239858A patent/CN101478951A/zh active Pending
- 2007-06-21 CN CN2013100083584A patent/CN103071157A/zh active Pending
- 2007-06-21 JP JP2009517127A patent/JP5205374B2/ja not_active Expired - Fee Related
- 2007-06-21 DK DK07730288.3T patent/DK2032123T3/da active
- 2007-06-21 AT AT07730288T patent/ATE455534T1/de active
- 2007-06-21 BR BRPI0713298-0A patent/BRPI0713298A2/pt not_active IP Right Cessation
- 2007-06-29 AR ARP070102948A patent/AR061771A1/es unknown
-
2008
- 2008-12-24 CO CO08136879A patent/CO6140022A2/es unknown
-
2009
- 2009-01-07 NO NO20090095A patent/NO20090095L/no not_active Application Discontinuation
- 2009-01-22 MA MA31583A patent/MA30597B1/fr unknown
- 2009-05-05 HK HK09104134.0A patent/HK1128587A1/xx not_active IP Right Cessation
-
2010
- 2010-03-18 HR HR20100159T patent/HRP20100159T1/hr unknown
- 2010-03-19 CY CY20101100256T patent/CY1109910T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008016508A (es) | 2009-04-22 |
| DE602007004486D1 (de) | 2010-03-11 |
| SI2032123T1 (sl) | 2010-04-30 |
| PL2032123T3 (pl) | 2010-06-30 |
| CN101478951A (zh) | 2009-07-08 |
| EP1872775A1 (en) | 2008-01-02 |
| CO6140022A2 (es) | 2010-03-19 |
| EA018257B1 (ru) | 2013-06-28 |
| WO2008000683A1 (en) | 2008-01-03 |
| KR20090033341A (ko) | 2009-04-02 |
| EP2032123A1 (en) | 2009-03-11 |
| AR061771A1 (es) | 2008-09-17 |
| PT2032123E (pt) | 2010-04-07 |
| JP2009541419A (ja) | 2009-11-26 |
| ES2339069T3 (es) | 2010-05-14 |
| CY1109910T1 (el) | 2014-09-10 |
| KR101443149B1 (ko) | 2014-09-23 |
| CA2652226A1 (en) | 2008-01-03 |
| CN103071157A (zh) | 2013-05-01 |
| EA200900087A1 (ru) | 2009-06-30 |
| NO20090095L (no) | 2009-01-07 |
| CA2652226C (en) | 2014-08-12 |
| ATE455534T1 (de) | 2010-02-15 |
| JP5205374B2 (ja) | 2013-06-05 |
| DK2032123T3 (da) | 2010-03-08 |
| US20110091555A1 (en) | 2011-04-21 |
| BRPI0713298A2 (pt) | 2012-04-17 |
| MA30597B1 (fr) | 2009-07-01 |
| US8865201B2 (en) | 2014-10-21 |
| RS51279B (sr) | 2010-12-31 |
| HK1128587A1 (en) | 2009-10-30 |
| EP2032123B1 (en) | 2010-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100159T1 (hr) | Upotreba hidrofilnog matriksa koji se sastoji od derivata poliakrilne kiseline, celuloznog etera i sredstva za raspadanje u proizvodnji medikamenta za liječenje ženskih genitalnih poremećaja | |
| JP2009541419A5 (hr) | ||
| Acarturk | Mucoadhesive vaginal drug delivery systems | |
| JP7219712B2 (ja) | 膣送達のための凍結乾燥医薬組成物 | |
| MX339071B (es) | Almidon pregelatinizado en una formulacion de liberacion controlada. | |
| JP2004508296A5 (hr) | ||
| HRP20211968T1 (hr) | Orodisperzibilna jedinica za doziranje koja sadrži komponentu estetrola | |
| RU2007137434A (ru) | Таблетированный препарат с замедленным высвобождением для вертиго | |
| PH12020550009A1 (en) | Pharmaceutical preparation and preparation method therefor | |
| HRP20231670T1 (hr) | Farmaceutski pripravak za oralnu primjenu koji sadrži derivat aminopirimidina ili njegovu sol | |
| RU2008136767A (ru) | Фармацевтическая композиция флувастатина натрия | |
| US20090030052A1 (en) | Pharmaceutical tablet compositions containing irbesartan | |
| JP2010521437A5 (hr) | ||
| RU2009138048A (ru) | Дозированные формы с задержанным на определенное время пульсирующим высвобождением | |
| KR20190038881A (ko) | 무정형 소포스부비르를 포함하는 고체 제약 조성물 | |
| WO2019013583A3 (ko) | 약제학적 제제 및 그 제조방법 | |
| FI3609493T3 (fi) | Furatsidiini gardnerella vaginaliksen tai atopium vaginaen aiheuttaman emättimen bakteeri-infektion hoitoon | |
| AU2002311622A1 (en) | Long acting compositions comprising zidovudine and lamivudine | |
| WO2019083483A2 (en) | VAGINAL IMPLANT | |
| WO2017200413A1 (ru) | Средства для лечения инфекционных заболеваний, передаваемых половым путём | |
| CN103505459A (zh) | 利奈唑胺药物组合物 |